Assessing Patient Impact From Recalls Often A Judgment Call, US FDA Says
Executive Summary
Industry participants on an FDA-convened webinar asked for further guidance on how to evaluate the effects enforcement actions might have on patients and the public health. The webinar was organized to discuss a recent FDA draft guidance on benefit-risk considerations for post-market decisions.
You may also be interested in...
FDA Finalizes Post-Market Benefit-Risk Guidance
The guidance document attempts to help manufacturers and the agency consistently apply benefit-risk factors in making decisions about non-conforming products on the market and regulatory compliance issues. It is part of FDA’s larger effort to harmonize risk-benefit standards throughout the agency’s device center.
FDA, AAMI Explore How To Consider Benefits, Risks In Postmarket
FDA has already put a lot of work into mapping out pathways for weighing benefit versus risk in premarket review decisions. Now the agency, with the help of the Association for the Advancement of Medical Instrumentation and industry, is trying to provide the same support for compliance and enforcement decisions.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.